There is a need for novel oral antidiuretics to treat diseases, such as pituitary diabetes insipidus and nephrogenic diabetes insipidus; however, investigations for compounds other than the typically used arginine vasopressin (AVP) or desmopressin are lacking. This evidence concerns the gene AVP and neurohypophyseal diabetes insipidus.